Review
Clinical Neurology
Junqiang Yan, Hongxia Ma, Anran Liu, Jiarui Huang, Jiannan Wu, Jianxue Yang
Summary: Rotigotine transdermal patch has a positive effect on neuropsychiatric symptoms in patients with Parkinson's disease, significantly improving scores in various assessments, especially in terms of sleep quality and overall quality of life.
FRONTIERS IN NEUROLOGY
(2021)
Article
Clinical Neurology
Fernando L. Pagan, Barbara Wilmarth, Yasar Torres-Yaghi, Michaeline L. Hebron, Sanjana Mulki, Dalila Ferrante, Sara Matar, Jaeil Ahn, Charbel Moussa
Summary: The study showed that nilotinib is safe and well tolerated in Parkinson's disease patients. Clinical data indicated that nilotinib 300mg had stable effects on Parkinson's symptoms, while the 150mg dose showed significant declines. Starting with the 150mg dose late in the disease progression worsened symptoms, and quality of life decreased with 150mg but remained stable with 300mg.
MOVEMENT DISORDERS
(2021)
Review
Clinical Neurology
Weibo Sun, Qingyong Wang, Tiansong Yang, Chuwen Feng, Yuanyuan Qu, Yan Yang, Chaoran Li, Zhongren Sun, Tetsuya Asakawa
Summary: This meta-analysis evaluated the effects of rotigotine transdermal patch (TP) on motor performance, activities of daily living (ADL) limitations, and sleep disturbances in patients with Parkinson's disease (PD). The results showed that rotigotine TP significantly improved movement symptoms, ADL limitations, and sleep quality without increasing adverse events. This study provides compelling evidence for the clinical usage of rotigotine TP.
NEUROLOGICAL SCIENCES
(2022)
Article
Clinical Neurology
Danilo Genovese, Francesco Bove, Leonardo Rigon, Tommaso Tufo, Alessandro Izzo, Paolo Calabresi, Anna Rita Bentivoglio, Carla Piano
Summary: This study assessed the clinical safety and efficacy of frameless bilateral subthalamic nucleus deep brain stimulation (STN-DBS) in Parkinson's disease (PD) patients at 5 years after surgery. The results demonstrate that this technique is safe and well-tolerated, with sustained motor efficacy at 5 years post-surgery.
NEUROLOGICAL SCIENCES
(2023)
Article
Clinical Neurology
Hideki Mochizuki, Nobutaka Hattori, Kazuko Hasegawa, Masahiro Nomoto, Eiji Uchida, Takaaki Terahara, Koji Okawa, Hiroyuki Fukuta
Summary: This study evaluated the long-term efficacy and safety of the ropinirole hydrochloride patch for Parkinson's disease, showing significant improvement in symptoms and a steady increase in plasma concentration proportional to the dose.
PARKINSONISM & RELATED DISORDERS
(2021)
Article
Medicine, General & Internal
Katherine E. Olson, Krista L. Namminga, Yaman Lu, Aaron D. Schwab, Mackenzie J. Thurston, Mai M. Abdelmoaty, Vikas Kumar, Melinda Wojtkiewicz, Helen Obaro, Pamela Santamaria, R. Lee Mosley, Howard E. Gendelman
Summary: The study showed that long-term treatment with 3 micrograms/kilogram/day of sargramostim significantly reduced the number and severity of adverse events, while improving immune function and alleviating Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale scores. This dosage regimen is effective and well-tolerated for restoring immune homeostasis.
Article
Biochemistry & Molecular Biology
Dagmar H. Hepp, Thecla A. van Wageningen, Kirsten L. Kuiper, Karin D. van Dijk, Linda P. Oosterveld, Henk W. Berendse, Wilma D. J. van de Berg
Summary: An altered immune response has been found in Parkinson's disease, with specific blood proteins associated with disease severity. Over time, the expression levels of inflammation-associated proteins may increase and are correlated with the severity of motor and cognitive symptoms.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Clinical Neurology
Federica Garri, Francesco Paolo Russo, Tommaso Carrer, Luca Weis, Francesca Pistonesi, Michele Mainardi, Michele Sandre, Edoardo Savarino, Fabio Farinati, Francesca Del Sorbo, Paola Soliveri, Daniela Calandrella, Roberta Biundo, Miryam Carecchio, Anna Lena Zecchinelli, Gianni Pezzoli, Angelo Antonini
Summary: This study retrospectively analyzed the usage of LCIG in 79 patients with Parkinson's disease and found that it has a relatively satisfactory long-term safety profile and efficacy, with a low rate of discontinuation. Peristomal complications may be a predictor of longer duration of therapy.
JOURNAL OF NEUROLOGY
(2022)
Article
Clinical Neurology
Atsushi Takeda, Ryosuke Takahashi, Yoshio Tsuboi, Masahiro Nomoto, Tetsuya Maeda, Akihisa Nishimura, Kazuo Yoshida, Nobutaka Hattori
Summary: The double-blind part of the COMFORT-PD study in Japanese levodopa-treated patients with Parkinson's disease and motor fluctuations showed that both opicapone 25 and 50 mg were more effective than placebo. The 52-week open-label extension study demonstrated that opicapone 50 mg tablets were well tolerated and consistently reduced OFF-time in patients who completed the initial double-blind part of the study.
JOURNAL OF NEURAL TRANSMISSION
(2021)
Article
Multidisciplinary Sciences
Annalisa Gessani, Francesco Cavallieri, Valentina Fioravanti, Isabella Campanini, Andrea Merlo, Giulia Di Rauso, Benedetta Damiano, Sara Scaltriti, Elisa Bardi, Maria Giulia Corni, Francesca Antonelli, Francesca Cavalleri, Maria Angela Molinari, Sara Contardi, Elisa Menozzi, Alessandro Fraternali, Annibale Versari, Giuseppe Biagini, Valerie Fraix, Serge Pinto, Elena Moro, Carla Budriesi, Franco Valzania
Summary: This study aimed to evaluate the long-term effects of bilateral subthalamic nucleus deep brain stimulation (STN-DBS) on speech in advanced Parkinson's Disease (PD) patients. The results showed that speech intelligibility stayed at the same level as preoperative values in the long-term follow-up. However, there was a significant acute improvement of speech intelligibility in the postoperative assessment.
SCIENTIFIC REPORTS
(2023)
Article
Clinical Neurology
Yue Hui Lau, Valentina Leta, Katarina Rukavina, Miriam Parry, Jenny Ann Natividad, Vinod Metta, Guy Chung-Faye, K. Ray Chaudhuri
Summary: The study evaluated the tolerability and beneficial effects of combined therapy with overnight rotigotine transdermal patch and intrajejunal levodopa infusion in advanced Parkinson's disease over a 12-month follow-up period. The results showed that the combined therapy was well tolerated and led to improved aspects of mood and apathy sustained at 12 months.
JOURNAL OF NEURAL TRANSMISSION
(2022)
Article
Instruments & Instrumentation
Xiaxia Wu, Dongfang Cheng, Yue Lu, Rong Rong, Ying Kong, Xiuzhi Wang, Baohua Niu
Summary: In this study, a new method for treating Parkinson's disease (PD) using a long-acting slow-release gel called RTG-gel was developed. The gel exhibited favorable rheological properties and sustained release capabilities, with minimal irritation to the injection site and good biocompatibility.
DRUG DELIVERY AND TRANSLATIONAL RESEARCH
(2023)
Article
Clinical Neurology
Hana Brozova, Isabelle Barnaure, Evzen Ruzicka, Jan Stochl, Ron Alterman, Michele Tagliati
Summary: The study aimed to compare the short and long-term effects of subthalamic nucleus (STN) deep brain stimulation (DBS) on gait dysfunction and other cardinal symptoms of Parkinson's disease (PD). The results showed that short-term improvement of gait abnormalities appears to significantly decline after 5 years of STN DBS in PD patients, while effectiveness for other symptoms remains stable. This suggests that non-dopaminergic mechanisms or deleterious effects of high frequency STN stimulation might play a role in the decline of gait function over time.
FRONTIERS IN NEUROLOGY
(2021)
Article
Clinical Neurology
Alfonso Fasano, Rocio Garcia-Ramos, Tanya Gurevich, Robert Jech, Lars Bergmann, Olga Sanchez-Solino, Juan Carlos Parra, Mihaela Simu
Summary: A multinational retrospective study found that long-term use of levodopa-carbidopa intestinal gel (LCIG) can improve motor and nonmotor symptoms in patients with Parkinson's disease, while potentially reducing the need for additional medications.
JOURNAL OF NEUROLOGY
(2023)
Article
Engineering, Biomedical
Van Dat Bui, Soyoung Son, Wilbin Xavier, Van Quy Nguyen, Jae Min Jung, Jungmi Lee, Sol Shin, Wooram Um, Jae Yoon An, Chan Ho Kim, Yeari Song, Yuce Li, Jae Hyung Park
Summary: This study investigated the feasibility of extracellular vesicles (EVs) for clinical applications and prepared hyaluronic acid dissolving microneedles loaded with human adipose stem cell-derived EVs (EV@MN) with long-term stability. The EV@MN enabled precise and convenient intradermal delivery of EVs, significantly improving the biological functions of dermal fibroblasts.
Article
Clinical Neurology
Jun-Pyo Hong, Hanim Kwon, Euyhyun Park, Sun-Uk Lee, Chan-Nyoung Lee, Byung-Jo Kim, Ji-Soo Kim, Kun-Woo Park
Summary: In patients with mild-to-moderate PD, vestibular function assessed by video head-impulse tests appears relatively preserved and has minimal impact on the risk of falls. Risk of postural instability is associated with the severity of clinical symptoms in PD.
PARKINSONISM & RELATED DISORDERS
(2024)
Article
Clinical Neurology
Yaqin Xiang, XiuRong Huang, Qian Xu, Zhenhua Liu, Yase Chen, Qiying Sun, Junling Wang, Hong Jiang, Lu Shen, Xinxiang Yan, Beisha Tang, Jifeng Guo
Summary: Using the novel data-driven method DEBM, this study determined the sequence of several common biomarker changes in Parkinson's disease (PD). The left putamen was found to be the earliest biomarker to become abnormal, followed by the right putamen, CSF alpha-synuclein, right caudate, left caudate, and serum NfL. The estimated disease stages showed significant differences between PD and healthy controls, and achieved a high accuracy for distinguishing PD from HC.
PARKINSONISM & RELATED DISORDERS
(2024)
Article
Clinical Neurology
Yan Li, David J. McLernon, Carl E. Counsell, Angus D. Macleod
Summary: This study aimed to investigate the incidence and risk factors for institutionalisation in Parkinson's disease (PD) and atypical parkinsonism (AP). The study found that institutionalisation was more frequent in AP compared to PD and controls. Age, poorer cognition, and more-severe parkinsonian impairment were independent predictors of institutionalisation.
PARKINSONISM & RELATED DISORDERS
(2024)